{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:16:32Z","timestamp":1790770592556,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011970","name":"International Team for Implantology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ophtha.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T19:34:08Z","timestamp":1747683248000},"page":"1142-1151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-0111","authenticated-orcid":false,"given":"Jui-En","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-2749","authenticated-orcid":false,"given":"Giuseppe","family":"Barbesino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl_1","key":"10.1016\/j.ophtha.2025.05.012_bib1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.ophtha.2025.05.012_bib2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ophtha.2025.05.012_bib3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ophtha.2025.05.012_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2025.05.012_bib5","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1210\/jc.2013-4184","article-title":"Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study","volume":"99","author":"Selmer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ophtha.2025.05.012_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.14797\/mdcj-13-2-60","article-title":"Hyperthyroidism and the heart","volume":"13","author":"Osuna","year":"2017","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"15","key":"10.1016\/j.ophtha.2025.05.012_bib7","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ophtha.2025.05.012_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"12","key":"10.1016\/j.ophtha.2025.05.012_bib9","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ophtha.2025.05.012_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ophtha.2025.05.012_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye (Lond)"},{"issue":"18","key":"10.1016\/j.ophtha.2025.05.012_bib12","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ophtha.2025.05.012_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2025.05.012_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tem.2013.12.002","article-title":"New insights into IGF-1 signaling in the heart","volume":"25","author":"Troncoso","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ophtha.2025.05.012_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13443","article-title":"The antagonistic pleiotropy of insulin-like growth factor 1","volume":"20","author":"Zhang","year":"2021","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.ophtha.2025.05.012_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12933-023-01916-2","article-title":"Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial","volume":"22","author":"Mohebi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ophtha.2025.05.012_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2024.10.029","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation","volume":"271","author":"Eng","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2025.05.012_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2023.6089","article-title":"Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis","volume":"142","author":"Huang","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.05.012_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ophtha.2025.05.012_bib18","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1210\/clinem\/dgad212","article-title":"IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg","volume":"108","author":"Mukama","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ophtha.2025.05.012_bib19","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/jc.2012-2268","article-title":"Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons","volume":"97","author":"Brandt","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ophtha.2025.05.012_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2025.05.012_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.05.012_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:10:57Z","timestamp":1778944257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0161642025003100"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.05.012","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}